Today: 29 April 2026
Uber stock slides despite CES robotaxi push — what traders watch next week

Uber stock slides despite CES robotaxi push — what traders watch next week

New York, Jan 10, 2026, 17:30 EST — Market closed

Uber Technologies, Inc. shares (UBER.N) slipped 2.45% on Friday, closing at $85.44 and ending a three-day rally. The Nasdaq, meanwhile, moved higher. The stock remains roughly 16% below its 52-week peak, with volume trailing the 50-day average, MarketWatch data show.

Autonomous-driving buzz lingered as Reuters reported Nvidia and several auto suppliers unveiled new partnerships at CES in Las Vegas, aiming to slash costs and accelerate rollout. Nvidia’s upcoming platform will power a robotaxi venture from Lucid, Nuro, and Uber, Reuters noted. Meanwhile, rivals like Tesla and Alphabet’s Waymo continue to develop their systems in-house. Amazon Web Services’ automotive lead, Ozgur Tohumcu, described AI and generative AI as a “big accelerant” for both development and validation. Reuters

Autonomy matters for Uber now because it’s one of the few topics that can shift the stock outside of earnings reports. Driverless fleets might eventually cut one of ride-hailing’s biggest expenses — but they could also hand more power to whoever controls the vehicles and the software behind them.

Uber bulls argue the company can dominate as a demand hub, connecting trips between humans and machines. Bears counter that, even with robotaxis, the app might not capture the best economics.

The math doesn’t add up easily. In a robotaxi scenario, the operator could claim the bulk of each fare, which would squeeze Uber’s take rate — the revenue share from rides booked — leaving little wiggle room for margin gains.

Uber’s next major event is its earnings report. The company hasn’t officially set a date yet, but Wall Street Horizon points to Feb. 4 as a possible release day before the market opens. Investors will be watching closely to see how Uber’s results stack up against its prior guidance, which pegged fourth-quarter gross bookings—the total value of rides, delivery, and other orders—between $52.25 billion and $53.75 billion. Adjusted EBITDA, a key cash-profit metric, was expected in the range of $2.41 billion to $2.51 billion.

Traders will be eyeing Uber on Monday to see if it can stay in the mid-$80s following Friday’s drop, or if the stock slips back to the price points that attracted buyers earlier this month.

Macro factors are also at play. The Federal Reserve’s upcoming policy meeting, set for Jan. 27-28, could shake up rate-sensitive growth stocks well ahead of the official statement.

The next key milestone arrives quickly: the U.S. consumer price index for December is scheduled for release Tuesday, Jan. 13 at 8:30 a.m. ET. This report frequently influences risk appetite, especially among high-multiple stocks.

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:55 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Intel stock jumps 11% on Trump praise — what INTC investors watch next
Previous Story

Intel stock jumps 11% on Trump praise — what INTC investors watch next

Ford stock pulls back from rally as ‘eyes-off’ driving plan and Piper upgrade hit tape
Next Story

Ford stock pulls back from rally as ‘eyes-off’ driving plan and Piper upgrade hit tape

Go toTop